{
  "id": "5c73acf27c78d6947100008a",
  "type": "yesno",
  "question": "Is Semagacestat effective for treatment of Alzheimer's disease?",
  "ideal_answer": "No. In clinical trial semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
    "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
    "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
    "http://www.ncbi.nlm.nih.gov/pubmed/23196551",
    "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
    "http://www.ncbi.nlm.nih.gov/pubmed/25292430",
    "http://www.ncbi.nlm.nih.gov/pubmed/21149978",
    "http://www.ncbi.nlm.nih.gov/pubmed/28978478"
  ],
  "snippets": [
    {
      "text": "However, a large phase 3 trial of semagacestat, a potential non-transition state analog (non-TSA) GSI, in patients with Alzheimer's disease (AD) was terminated due to unexpected aggravation of cognitive deficits and side effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978478",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A clinical trial with the wide-spectrum \u03b3-secretase inhibitor semagacestat has, however, demonstrated that global inhibition of all \u03b3-secretases causes serious toxicity. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25292430",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND\nIn a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Semagacestat was associated with more adverse events, including skin cancers and infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS\nAs compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE\nSemagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently disclosed Phase III findings on semagacestat indicated that Alzheimer's disease (AD) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23785331",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The recent failure of semagacestat in two large Phase III studies questions the value of \u03b3-secretase inhibitors in treating Alzheimer's disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21149978",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase 3 trial of semagacestat for treatment of Alzheimer's disease.As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Preliminary results from Phase III studies showed that semagacestat failed to slow disease progression, and it was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23196551",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of\u00a0Alzheimer's Disease.In participants with mild to moderate AD, high dose semagacestat treatment was associated with greater severity and faster worsening of NPS in a pattern resembling an agitated depression. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27567808",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<b>OBJECTIVE</b>: Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin-related TEAEs, renal and hepatic changes, increased QT interval, and weight loss.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P&lt;0.001 for all comparisons with placebo).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23883379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Semagacestat, a \u03b3-secretase inhibitor, demonstrated an unfavorable risk-benefit profile in a Phase 3 study of patients with Alzheimer's disease (IDENTITY trials), and clinical development was halted.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24983746",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}